Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

NCT02852798 · clinicaltrials.gov ↗

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Nonsquamous Nonsmall Cell Neoplasm of Lung

Interventions

DRUG: Apatinib Combined With Docetaxel

Sponsor

Jiangsu ShengDiYa Medicine Co., Ltd.

Collaborators

[object Object]